Abstract
Buprenorphine is a partial agonist at the μ-opioid receptor with long duration of action and also exhibits delayed antagonist activity. Buprenorphine is finding increasing use as a treatment agent for opioid abuse, though its low efficacy is not well tolerated by all addicts. There is interest in developing a higher efficacy version of buprenorphine and in this mini-review some of the ligands recently discovered, that share with buprenorphine a profile of agonism followed by delayed antagonism, are discussed.
Keywords: opioid ligands, long-term antagonistic activity, opioid abuse, buprenorphine, methadone
Mini-Reviews in Medicinal Chemistry
Title: Opioid Ligands Having Delayed Long-Term Antagonist Activity: Potential Pharmacotherapies for Opioid Abuse
Volume: 3 Issue: 2
Author(s): Stephen M. Husbands and John W. Lewis
Affiliation:
Keywords: opioid ligands, long-term antagonistic activity, opioid abuse, buprenorphine, methadone
Abstract: Buprenorphine is a partial agonist at the μ-opioid receptor with long duration of action and also exhibits delayed antagonist activity. Buprenorphine is finding increasing use as a treatment agent for opioid abuse, though its low efficacy is not well tolerated by all addicts. There is interest in developing a higher efficacy version of buprenorphine and in this mini-review some of the ligands recently discovered, that share with buprenorphine a profile of agonism followed by delayed antagonism, are discussed.
Export Options
About this article
Cite this article as:
Husbands M. Stephen and Lewis W. John, Opioid Ligands Having Delayed Long-Term Antagonist Activity: Potential Pharmacotherapies for Opioid Abuse, Mini-Reviews in Medicinal Chemistry 2003; 3 (2) . https://dx.doi.org/10.2174/1389557033405395
DOI https://dx.doi.org/10.2174/1389557033405395 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
Current Drug Targets Natural Products in Structure-Assisted Design of Molecular Cancer Therapeutics
Current Pharmaceutical Design Commentary Research Highlights: Untangling Alzheimer Disease Pathology
CNS & Neurological Disorders - Drug Targets Development of Tablet Device App for Parkinson’s Disease Patients’ Continuous Self-Monitoring and Management
Neuroscience and Biomedical Engineering (Discontinued) Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Transforming Growth Factor-Beta: A Potential New Agent for Pleurodesis
Drug Design Reviews - Online (Discontinued) Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews Logical Design of Medical Chaperone for Prion Diseases
Current Topics in Medicinal Chemistry Epigenetic Regulation of Memory-Therapeutic Potential for Disorders
Current Neuropharmacology Patent Selections:
Recent Patents on Biotechnology The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Cyberbullying and Depression Among Adolescents in an Acute Inpatient Psychiatric Hospital
Adolescent Psychiatry GHB, GBL and 1,4-BD Addiction
Current Pharmaceutical Design Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Depression in Adolescence: From Qualitative Research to Measurement
Adolescent Psychiatry Obstacles and Opportunities for Cholinergic Drug Development in the Treatment of Cognitive Disorders
Current Pharmaceutical Design Editorial [Hot topic: G-Protein Coupled Receptors: Drug Targets of Key Importance (Guest Editors: Luca Piali and Christoph Boss)]
Current Topics in Medicinal Chemistry